FLT3 and acute myeloid leukemia: To overcome some of these drawbacks related to the targeting of FLT3, one recent study reported the preclinical evaluation of an off-the-shelf CAR T cell therapy targeting FLT3 for the treatment of AML with reduced myelotoxicity while sparing anti-leukemic activity.